SynthesisKidney international. Supplement2009
Ticlopidine- and clopidogrel-associated thrombotic thrombocytopenic purpura (TTP): review of clinical, laboratory, epidemiological, and pharmacovigilance findings (1989-2008).
Synthesis in Kidney international. Supplement, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 96 citations in OpenAlex.
- Case report: use of thienopyridines in a patient with acquired idiopathic thrombotic thrombocytopenic purpura.Journal of thrombosis and thrombolysis · 2012Trial
- Thrombotic thrombocytopaenic purpura.European heart journal. Case reports · 2025Article
- Kidney Toxicity of Drugs for the Heart: An Updated Perspective.Metabolites · 2025Review
- A woman with eptifibatide (integrilin)-induced thrombocytopenia following treatment of a clot in her coronary artery: A case report and literature review.Clinical case reports · 2024Article
- Clopidogrel-induced thrombotic thrombocytopenic purpura: a case report.African health sciences · 2023Article
- Is Endothelial Activation a Critical Event in Thrombotic Thrombocytopenic Purpura?Journal of clinical medicine · 2023Review
- An 80-Year-Old Man with Ischemic Heart Disease Who Developed Thrombotic Thrombocytopenic Purpura Following Treatment with Ticagrelor.The American journal of case reports · 2022Article
- Drug-induced thrombotic microangiopathy: An updated review of causative drugs, pathophysiology, and management.Frontiers in pharmacology · 2022Review
- Potentially inappropriate medications in older Chinese outpatients based on the Beers criteria and Chinese criteria.Frontiers in pharmacology · 2022Article
- Immune Thrombotic Thrombocytopenic Purpura in a Patient with Suspected COVID-19: Hydroxychloroquine Culprit or Just Happenstance?Turkish journal of haematology : official journal of Turkish Society of Haematology · 2021Article
- Thrombotic microangiopathy (aHUS/iTTP) reported so far in Covid-19 patients: The virus alone or an omnium gatherum of mechanisms and etiologies?Critical reviews in oncology/hematology · 2021Article
- A rare case of eptifibatide-induced thrombocytopenia.Journal of community hospital internal medicine perspectives · 2021Article
- Thrombocytopenia in hospitalized patients: approach to the patient with thrombotic microangiopathy.Hematology. American Society of Hematology. Education Program · 2017Review
- When a Single Antiplatelet Agent for Stroke Prevention Is Not Enough: Current Evidence and Future Applications of Dual Antiplatelet Therapy.Current treatment options in cardiovascular medicine · 2016Article
- Prasugrel and Acquired Thrombotic Thrombocytopenic Purpura Associated with ADAMTS13 Activity Deficiency.European journal of case reports in internal medicine · 2016Article
- Clopidogrel-Associated Thrombotic Thrombocytopenic Purpura following Endovascular Treatment of Spontaneous Carotid Artery Dissection.Journal of neurological surgery reports · 2015Article
- The change in platelet count in patients with acute coronary syndrome 6 months after coronary stent implantation.Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis · 2015Article
- Drug-induced glomerular disease: direct cellular injury.Clinical journal of the American Society of Nephrology : CJASN · 2015Review
- Update on hemolytic uremic syndrome: Diagnostic and therapeutic recommendations.World journal of nephrology · 2013Review
- Thrombotic thrombocytopenic purpura (TTP)-like illness associated with intravenous Opana ER abuse--Tennessee, 2012.MMWR. Morbidity and mortality weekly report · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 9 institutions in 2 countries.
Funding
Abstract
Thrombotic thrombocytopenic purpura (TTP) is a fulminant disease characterized by platelet aggregates, thrombocytopenia, renal insufficiency, neurologic changes, and mechanical injury to erythrocytes. Most idiopathic cases of TTP are characterized by a deficiency of ADAMTS13 (a disintegrin and metalloprotease, with thrombospondin-1-like domains) metalloprotease activity. Ironically, use of anti-platelet agents, the thienopyridine derivates clopidogrel and ticlopidine, is associated with drug induced TTP. Data were abstracted from a systematic review of English-language literature for thienopyridine-associated TTP identified in MEDLINE, EMBASE, the public website of the Food and Drug Administration, and abstracts from national scientific conferences from 1991 to April 2008. Ticlopidine and clopidogrel are the two most common drugs associated with TTP in FDA safety databases. Epidemiological studies identify recent initiation of anti-platelet agents as the most common risk factor associated with risks of developing TTP. Laboratory studies indicate that most cases of thienopyridine-associated TTP involve an antibody to ADAMTS13 metalloprotease, present with severe thrombocytopenia, and respond to therapeutic plasma exchange (TPE); a minority of thienopyridine-associated TTP presents with severe renal insufficiency, involves direct endothelial cell damage, and is less responsive to TPE. The evaluation of this potentially fatal drug toxicity can serve as a template for future efforts to comprehensively characterize other severe adverse drug reactions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.